Podcast: Guardant Looking Ahead To Insurers, FDA On Liquid Biopsy

29 Jul 2016

Guardant Health recently announced that the first US health insurance plan covered its Guardant360 liquid biopsy system. CEO Helmy Eltoukhy spoke to Medtech Insight about the milestone and the firm's plans to gain FDA approval as the agency moves to oversee laboratory-developed tests. Read the story and listen to the podcast interview.

Liquid biopsy, which promises to replace tissue biopsies with blood tests during cancer care, is beginning to accelerate from the research bench to the clinic in the US. And, with that, comes the prying eyes of regulators and payers.

Guardant Health Inc. is one company at the forefront of this shift for the closely watched technology. Earlier in...